The echinocandin susceptibilities of 122 Candida glabrata complex strains (including 5 Candida nivariensis and 3 Candida bracarensis strains) were evaluated by microdilution and compared with the results from a molecular tool able to detect FKS mutations. No echinocandin resistance was detected. The PCR results coincide with the MIC data in 99.25% of the cases (1 C. glabrata strain was misidentified as resistant) but were 20 h faster. C. nivariensis FKS genes were sequenced and showed differences with C. glabrata FKS genes.
T he epidemiology of Candida infections has undergone recent changes due to the description of cryptic species. Candida glabrata species complex includes three human-pathogenic species: C. glabrata sensu stricto, C. nivariensis, and C. bracarensis (1, 2) . Candida glabrata sensu stricto accounts for 15 to 20% of all cases of Candida infections worldwide, and it is the second most common cause of candidemia in the United States (3, 4) . In Latin American countries, such as Argentina, C. glabrata ranked fourth, representing 4% of the candidemia cases (5) .
C. glabrata infection treatment is often difficult due to the increasing prevalence of azole resistance. Thus, the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the Infectious Diseases Society of America (IDSA) have proposed echinocandins as the treatment of choice for these infections (6) (7) (8) . In recent years, the prevalence of echinocandin resistance in C. glabrata sensu stricto has increased (9, 10) . On the other hand, there are little data about echinocandin susceptibilities for the other two species of the complex, and no treatment recommendations have been released. However, the few available data support them being susceptible to echinocandins (11) (12) (13) (14) . Clinical resistance to echinocandins has been associated with hot spot FKS mutations (15, 16) . Recently, our group published a set of classical PCRs able to detect these mutations (17) . The aims of this study were to evaluate the in vitro activities of echinocandins against Argentinian C. glabrata sensu lato strains and to compare the obtained results with those obtained with the described molecular tool.
We analyzed a collection of 122 C. glabrata complex clinical strains, including: (i) 114 C. glabrata sensu stricto strains (40 isolated from blood, 17 from other normally sterile sites, 20 from the vagina, 14 from urine, 7 from the oral cavity, 2 from a catheter, 1 from stool, and 13 with no origin data), (ii) five C. nivariensis strains (throat, renal catheter, urine, continuous peritoneal dialysis bag, and 1 isolate with no isolation data available), and (iii) three C. bracarensis strains (urine, throat, and 1 with no data). All strains were randomly referred from several medical centers from 1984 to 2014 to the Argentinian National Culture Collection of Instituto Nacional de Microbiología Dr. Carlos G. Malbrán. The isolates were identified by classical, molecular (internal transcribed spacer [ITS] sequencing and multiplex PCR), and proteomic (matrix-assisted laser desorption ionization-time of flight mass spectrometry [MALDI-TOF MS]) methods (18) (19) (20) . Also, 17 characterized echinocandin-resistant C. glabrata sensu stricto strains harboring different FKS mutations were used as PCR control (17), together with Candida parapsilosis sensu stricto ATCC 22019 and Candida krusei ATCC 6258, which were used as MIC controls (21, 22) . Anidulafungin (ANF) and caspofungin (CSF) MICs were determined by broth microdilution in accordance with the CLSI M27-A3 and M27-S4 documents (21, 22) . Three of the isolates (C. nivariensis DMic 144820 and C. bracarensis DMic 144819 and DMic 144835) did not grow in RPMI 1640 broth, and susceptibility testing was performed by agar diffusion using Etest strips in RPMI 1640 agar. Echinocandin resistance molecular mechanisms were evaluated by using a recently published set of classical PCRs able to identify hot spot mutations at the FKS1 and FKS2 genes. FKS gene sequencing was used to confirm the obtained results (17) .
Echinocandins showed good in vitro activity against all the studied isolates (for C. nivariensis, ANF, 0.015 to 0.03 mg/liter, and CSF, 0.06 to 0.13 mg/liter; for C. bracarensis, ANF, 0.03 to 0.06 mg/liter, and CSF, 0.015 to 0.06 mg/liter; and for C. glabrata sensu stricto, ANF, 0.015 to 0.06 mg/liter, and CSF, 0.015 to 0.25 mg/liter). Turning to the molecular detection of FKS mutants, all but one C. glabrata sensu stricto strain showed a wild-type band pattern for the FKS1 and FKS2 hot spot regions (17) . Strain DMic 982958 showed a molecular profile consistent with a substitution at Fks1p (S629). The FKS genes of this strain were sequenced. FKS1 showed a silent mutation (T1888C and no amino acid substitution) that was detected but represents a false-positive result (minor error) ( Fig. 1A) .
All C. nivariensis strains showed a molecular profile consistent with a C. glabrata sensu stricto FKS mutant (a single band, using the Dudiuk et al. method [17] ) (Fig. 1B) . These C. nivariensis FKS genes were sequenced by using FKS universal primers (23) and showed several nucleotide differences compared with C. glabrata sensu stricto FKS genes. However, all the described naturally occurring polymorphisms yielded no amino acid changes. For C. bracarensis, it was not possible to obtain PCR bands by using the same primers.
C. glabrata strains with FKS mutations and reduced echinocandin susceptibilities have been described worldwide (10, 11, 15 ). The prevalences of such mutations ranged from 2.9% to 18% in different reports from different U.S. centers (9, 24, 25) . Neither elevated MIC values nor FKS hot spot mutations were detected in our strains. These results are in accordance with other reports from Latin America (26) . These geographical differences might be due to the higher use of echinocandin drugs in the United States. Beyda et al. suggested that the unique predictor for echinocandin resistance related to FKS mutations is the use of echinocandin drugs in clinical practice (24) . In Argentina, the use of these drugs is very scarce and could greatly contribute to the inexistence of such resistance in our collection.
All C. bracarensis and C. nivariensis isolates showed low echinocandin MIC values and were consistent with previous reports (11, 12, 14) .
Shields et al. considered that FKS mutation detection is the most significant risk factor for therapy failure for C. glabrata infections (16) . The PCR method used in this work showed 99.25% accordance with susceptibility testing for C. glabrata sensu stricto, and it is at least 20 h faster (17) (95.1% accordance if cryptic species were included). The unique false results (minor error) obtained for the described C. glabrata sensu stricto strain were due to a silent mutation at the hot spot 1 region of FKS1. In addition, this PCR method would be a suitable tool to circumvent the technical problems reported for caspofungin susceptibility testing (27) .
Turning to the cryptic species of the C. glabrata complex, the PCR set was unable to correctly classify them regarding echinocandin susceptibility. All C. nivariensis strains were incorrectly considered echinocandin resistant, owing to naturally occurring silent substitutions, while no PCR bands were obtained for C. bracarensis. Thus, we suggest identifying the cryptic species using PCR (18) or MALDI-TOF MS in order to improve the specificity and sensitivity of the molecular detection of echinocandin resistance.
Accession number(s). The nucleotide sequences for C. nivariensis FKS1 and FKS2 genes were deposited in GenBank under the accession numbers KY323706 and KY494841, respectively (Fig. 1C ).
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